Learn More2022-05-24 12:00:002022-05-24 13:00:00America/New_YorkPenn Bioethics Seminar Series: Kimani Paul-Emile, JD, PhD
FRAMING DRUGS: BATTLES OVER DRUG REGULATION AND HOW THEY CHANGED AMERICA
Kimani Paul-Emile, JD, PhD
Professor, Fordham University School of Law
Associate Director, Center on Race, Law & Justice
Faculty Co-Director, Stein Center for Law & Ethics
[This talk will NOT be recorded.]
Abstract: Drug regulations often seem inconsistent and incoherent, running counter to science and medicine. Tobacco, for example, can kill you, while anabolic steroids won’t, but you can purchase the former over the counter but not the latter. In addition, the way any particular drug is regulated can change over time even though scientific and medical knowledge regarding the drug remains unchanged. Thus, cannabis was once subject to some of the most rigid restrictions of any drug but is now on the cusp of total legalization. There is, however, a method to the madness, and this book examines that method, along with its social, legal, and cultural implications. Drug regulatory decision-making does much more than simply determine whether and under what circumstances certain drugs can be manufactured, purchased, and consumed. It also works under the surface to quietly shape popular understandings for race, instantiate gender roles, buttress capitalism, and undermine of the welfare state. This is particularly true for drugs that were at one time contested, such as cocaine, cannabis, anabolic steroids, patent medicines, opium, alcohol, OxyContin, tobacco, and contraception.
This book introduces “drug framing,” a heuristic for understanding how regulatory decisions regarding contested drugs are made. According to this heuristic, regulatory decision-making with respect to contested drugs is most accurately described as a high-stakes battle over how to convincingly frame a drug in accordance with the principles of a group’s preferred category: the medicine, consumer product, or social threat. Framing is, therefore, the allocation of meaning that precedes the legal or legislative work of drafting laws and regulations. Focusing on the pivotal, liminal, turning point when a drug is shifting from being understood as a medicine, consumer product, or social threat, this book illuminates how drug framing is used to change the popular meaning of particular drugs and their users. This enables regulators to treat drugs differently irrespective of the dangers the drugs may pose and independent of their health effects. In short, this book tells the story of contestation over drugs, how it occurs, what broader tensions it surfaces, and what it can tell us about the operation of power in America.
Dr. Kimani Paul-Emile is a Professor of Law; Associate Director and Head of Domestic Programs and Initiatives at Fordham Law School’s Center on Race, Law & Justice; and faculty co-director of the Fordham Law School Stein Center for Law & Ethics. Dr. Paul-Emile specializes in the areas of law & biomedical ethics, health law, anti-discrimination law, and race and the law.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-05-26 12:00:002022-05-26 13:00:00America/New_YorkHealth Policy + CHIBE Work-in-Progress Research Seminar: Mark L. Hatzenbuehler, PhD
Join us for a Work-in-Progress Research Seminar with Mark L. Hatzenbuehler, PhD, the John L. Loeb Associate Professor of the Social Sciences in the Department of Psychology at Harvard University. This event is hosted by CHIBE and the Perelman School of Medicine’s Division of Health Policy.
May 26, 2022
12:00-1:00 PM EST
Hybrid: 1104 Blockley Hall or https://upenn.zoom.us/j/95353951407
“A Contextual Approach to the Psychological Study of Stigma”
Psychological research has made significant advancements in the study of stigma. However, this work has been criticized for focusing almost exclusively on individual and interpersonal stigma processes to the exclusion of structural factors that promulgate stigma. To address this knowledge gap, researchers have expanded the stigma construct to consider how broader, macrosocial forms of stigma—what I call structural stigma—also disadvantage stigmatized individuals. In this talk, I will define the construct of structural stigma and describe how it differs from stigma at the individual and interpersonal levels. I will then review several studies from our research group that use a multi-measure, multi-method, and multi-outcome approach to document the negative biopsychosocial consequences of exposure to structural stigma. I will end the talk with a brief discussion of future directions for structural stigma research, as well as implications for preventive interventions aimed at reducing the negative health sequelae of structural stigma.
About Dr. Hatzenbuehler:
Mark L. Hatzenbuehler, PhD, is the John L. Loeb Associate Professor of the Social Sciences in the Department of Psychology at Harvard. He was previously an Associate Professor (with tenure) and Deputy Chair for Faculty Development and Research Strategy in the Department of Sociomedical Sciences at Columbia. Dr. Hatzenbuehler received his PhD in clinical psychology from Yale and completed his post-doctoral training in population health at Columbia, where he was a Robert Wood Johnson Foundation Health & Society Scholar. Dr. Hatzenbuehler’s work examines the role of stigma in shaping population health inequalities, with a particular focus on the mental health consequences of structural forms of stigma. His research has been continuously funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and through the William T. Grant Foundation Scholars Program. He has received several early career and distinguished contribution awards from the Society for the Psychological Study of Social Issues, the American Psychological Association, and the Association for Psychological Science. In 2020, he was one of only 200 social scientists named to the prestigious Highly Cited Researcher List by Clarivate Analytics in recognition of his research influence, as demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations for field and year in Web of Science. Dr. Hatzenbuehler is an elected fellow of the Academy of Behavioral Medicine Research, the premier honorary organization for scientists working at the interface of behavior and medicine, and he has been appointed to serve on two consensus committees at the National Academies of Sciences, Engineering, and Medicine.
Hybrid: 1104 Blockley Hall or ZoomPenn Medical Ethics
Learn More2022-05-31 12:00:002022-05-31 13:00:00America/New_YorkPenn Bioethics Seminar Series: Justin Clapp, PhD, MPH
Title TBA
Justin Clapp, PhD, MPH
Assistant Professor, University of Pennsylvania Perelman School of Medicine
Via Zoom. Register in advance:
https://upenn.zoom.us/meeting/register/tJMlcu2sqDkqHdB-3qW9vK4te9gzGR0y7A0V
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-06-06 12:00:002022-06-07 13:00:00America/New_YorkResearch Ethics and Policy Series & Abramson Cancer Center hosts: Jonathan Jackson, PhD
Monday, June 6 - Hosted by The department of Medical Ethics
Belmont’s Third Pillar: Towards Justice in Clinical Research
Tuesday, June 7 - Hosted by the Abramson Cancer Control Program
The Challenge of Quantifiable Research Representation
Time: 12:00-1:00p Eastern
Location: BRB 0252 Seminar Rm (Biomedical Research Building - 421 Curie Blvd)
HYBRID! Both events are in-person and via Zoom.
To-go lunches are provided to in-person attendees.
Bio: Jonathan Jackson, PhD, is the executive director of the Community Access, Recruitment, and Engagement (CARE) Research Center at Massachusetts General Hospital and is an Assistant Professor of Neurology at Harvard Medical School. CARE investigates the impact of diversity and inclusion on the quality of human subjects research and leverages deep community entrenchment to build trust and overcome barriers to clinical trial participation. Jonathan’s research focuses on inequities in clinical settings that affect underserved populations, and he has received generous funding for this work from the Michael J Fox Foundation for Parkinson’s Research, Massachusetts General Hospital, and the National Institutes of Health, including a prestigious NIH Pioneer Award to advance this work. Dr. Jackson, who received his doctoral degree in Psychological and Brain Sciences in 2014, also conducts research as a cognitive neuroscientist investigating the early detection of Alzheimer’s disease, particularly in the absence of overt memory problems. He has become a well-known representative to underserved communities and dozens of affiliated organizations, especially regarding participation in clinical research. Dr. Jackson serves in an advisory capacity for several organizations focused on equity in clinical research, and has written guidance for local, statewide, national, and federal organizations on research access, engagement, and recruitment.
------------
What to expect during the lecture:
In-person participants: We are following the University of Pennsylvania’s COVID-19 guidelines. All in-person attendees are encouraged to wear masks and must either show their Green PennOpen Pass (University of Pennsylvania faculty, students, postdocs, and staff or badged contractors) OR Green PennOpen Campus (all other visitors including event attendees) in order to take part in-person. Attendees must complete their screening on their cell phones or computers BEFORE arriving at the venue. Click here for more information about PennOpen Campus and how it works. To-go boxed lunches will be provided to in-person participants, to be eaten after the lecture.
Virtual participants: You will enter the virtual "waiting room" and will be admitted at noon Eastern. Your audio and video will be automatically muted upon entry and you will stay muted during the talk. You can submit questions to the chat box and a staff member will read it out-loud either during the talk or during the Q&A portion at the end.
------------
Information: Mary Pham, Mary.Pham@pennmedicine.upenn.edu
Hybrid: Biomedical Research Building - BRB 0252 Seminar Rm (421 Curie Blvd)Penn Medical Ethics
Learn More2022-06-07 12:00:002022-06-07 13:00:00America/New_YorkPenn Bioethics Seminar Series: Matthew McCoy, PhD
Title TBA
Name, title
Via Zoom. Register in advance:
[LINK]
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-06-14 12:00:002022-06-14 13:00:00America/New_YorkPenn Bioethics Seminar Series: Harsha Thirumurthy, PhD
Title TBA
Name, title
Via Zoom. Register in advance:
[LINK]
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-06-21 12:00:002022-06-21 13:00:00America/New_YorkPenn Bioethics Seminar Series: Christina A. Roberto, PhD
Title TBA
Name, title
Via Zoom. Register in advance:
[LINK]
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-06-28 12:00:002022-06-28 13:00:00America/New_YorkPenn Bioethics Seminar Series: Isha Marina Di Bartolo, MD
Title TBA
Name, title
Via Zoom. Register in advance:
[LINK]
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-07-05 12:00:002022-07-05 13:00:00America/New_YorkPenn Bioethics Seminar Series: Genevieve Kanter, PhD
Title TBA
Name, title
Via Zoom. Register in advance:
[LINK]
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics
Learn More2022-07-19 12:00:002022-07-19 13:00:00America/New_YorkPenn Bioethics Seminar Series: Ari B. Friedman, MD, PhD
Title TBA
Name, title
Via Zoom. Register in advance:
[LINK]
Abstract: To be shared.
For more information, contact Mary Pham, Mary.Pham@pennmedicine.upenn.edu.
via ZoomPenn Medical Ethics